Sign up
Pharma Capital

Prevecuetical Medical to develop treatment for anxiety

Anxiety disorders refer to a group of mental disorders characterized by feelings of anxiety and fear, including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder and posttraumatic stress disorder.
Anxiety attack
Symptoms typically experienced by those with anxiety disorders can make it a chronic disorder rather than an episodic disorder.

PreveCeutical Medical Inc (CNSX:PREV) said the first product of its newly-created medicinal cannabis division will be for the treatment of anxiety.

The company said the goal of its medicinal cannabis division's product development program is to create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.

READ PreveCeutical Medical shares head north as it launches medical cannabis division​

The Anxiety Disorders Association of Canada claims that one in four Canadians will suffer from an anxiety disorder at some point in their life.

Common treatments are not always effective and are known to have side effects, including insomnia, agitation and sexual dysfunction.  

Why Invest In PreveCeutical Medical Inc? Read More Here

Register here to be notified of future PREV Company articles
View full PREV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.